

Aerocrine

Swiss physicians to be reimbursed per NIOX MINO® test

SOLNA, Sweden 9 March 2009 Aerocrine AB (OMX Nordic Exchange: AERO) announced today that reimbursement for the routine measurement of airway inflammation has been introduced in the Swiss healthcare system.

From March 2009 onwards, specialists that measure airway inflammation using Aerocrine s NIOX MINO instrument will receive €36 per adult and €45 per child for each test. This reimbursement means that physicians specialising in airway diseases can use the test routinely in daily clinical work.

Asthma is one of the world s most widespread diseases, affecting more children than adults. Symptoms and asthma attacks are caused by inflammation in the airways. Measuring this inflammation was not possible in the past, so diagnosis and treatment was largely based on patient symptoms. Anti-inflammatory drugs, such as inhaled cortisone, are a cornerstone of asthma therapy. Measuring airway inflammation offers answers to which patients will respond to treatment, and provides an objective measure of therapeutic effect. By measuring inflammation regularly, doctors also get answers to whether patients are following their prescribed anti-inflammatory treatment, and that their asthma is under control. Regular measurement using NIOX MINO tests enable improved treatment and care of asthma patients, which in turn, is cost-effective.

This is a big success and milestone for Trimedal, our highly capable distributor in Switzerland, commented Paul de Potocki, Aerocrine s CEO, reimbursement from national health insurance systems is a vital prerequisite for the broad-based and routine usage of Aerocrine s products.

For more information, please contact:

Paul de Potocki, President &CEO, phone: +46 8 629 0782, 0706- 69 96 18
Lena Kajland-Wilén, Marketing Director, phone: +46 8 629 0784, 0706-29 07 84

About Aerocrine

Aerocrine AB is a medical technology company focused on the improved management and care of patients with inflammatory airway diseases. As the pioneer and leader in the technology to monitor and manage airway inflammation, Aerocrine markets NIOX® Flex and NIOX MINO®. Both products enable fast and reliable management of airway inflammation and may therefore play a critical role in more effective diagnosis, treatment and follow-up of patients with inflammatory airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries in the US, Germany and the UK. Aerocrine shares were listed on the Stockholm Stock Exchange on 15 June 2007.

Aerocrine may be required to disclose the information provided herein pursuant to the Securities Markets Act. The information was submitted for publication at 9.30 am on 9 March 2009.